Posted by Michael Wonder on 31 Aug 2021
Ligand’s Partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma
31 August 2021 - First regulatory approval of an OmniAb derived antibody.
Ligand Pharmaceuticals today announced that its partner Gloria Biosciences has received approval from China’s National Medical Products Administration for zimberelimab, an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma.
GloriaBio has development and commercialisation rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.
